Ultragenyx Pharmaceutical Inc. <RARE.O>: Baird cuts to neutral rating; cuts target price to $16 from $40
RARE•Related News
BlackRock lifts AB InBev stake to 3.25% voting rights
BUD•
Studsvik signs deal with GE Vernova Hitachi, Samsung C&T to build 1.2 GW nuclear capacity in Sweden
GEV•
Scotiabank: Jefferies Raises Target Price to C$120 from C$119
BNS•
Yen gets boost from hawkish BOJ repricing of rate expectations
TLT•
Implats FY26 headline earnings more than doubled to R22.87 billion; revenue rises 58% to R135.15 billion
IMPUY•